Screenshot courtesy of The Washington Post | Robert Williford, 67, receives a dose of Leqembi at Abington Neurological Associates in Abington, Pa. (Hannah Yoon for The Washington Post)
New Alzheimer’s drugs bring hope. But not equally for all patients.
A perplexing factor is at play — one that raises new, sensitive questions about the role of race, genetics and other factors.
Read in The Washington Post
